Free Trial

Kyverna Therapeutics (KYTX) Competitors

Kyverna Therapeutics logo
$6.40 -0.27 (-4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$6.32 -0.08 (-1.23%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KYTX vs. DNTH, UPB, AMPH, LENZ, PRAX, SPRY, RLAY, SEPN, SANA, and COLL

Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Dianthus Therapeutics (DNTH), Upstream Bio (UPB), Amphastar Pharmaceuticals (AMPH), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), ARS Pharmaceuticals (SPRY), Relay Therapeutics (RLAY), Septerna (SEPN), Sana Biotechnology (SANA), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

Kyverna Therapeutics vs. Its Competitors

Dianthus Therapeutics (NASDAQ:DNTH) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 8.2% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kyverna Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat Kyverna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dianthus Therapeutics-2,364.56% -34.72% -32.72%
Kyverna Therapeutics N/A -64.98%-56.17%

Dianthus Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.72, indicating that its share price is 272% more volatile than the S&P 500.

Dianthus Therapeutics currently has a consensus price target of $60.88, suggesting a potential upside of 82.97%. Kyverna Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 196.88%. Given Kyverna Therapeutics' higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Dianthus Therapeutics has higher earnings, but lower revenue than Kyverna Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dianthus Therapeutics$6.24M171.63-$84.97M-$3.25-10.24
Kyverna Therapeutics$7.03M39.37-$127.48M-$3.68-1.74

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 3 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.69 beat Kyverna Therapeutics' score of 0.48 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dianthus Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kyverna Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Dianthus Therapeutics beats Kyverna Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KYTX vs. The Competition

MetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$276.80M$3.43B$6.17B$10.66B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-1.7423.4029.6328.51
Price / Sales39.37477.72578.55129.15
Price / CashN/A45.5937.1261.42
Price / Book1.0410.3512.046.52
Net Income-$127.48M-$52.53M$3.32B$276.75M
7 Day Performance-8.70%-0.22%-0.16%0.20%
1 Month Performance1.43%10.89%5.76%1.67%
1 Year Performance28.26%14.19%65.69%32.72%

Kyverna Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KYTX
Kyverna Therapeutics
2.9636 of 5 stars
$6.40
-4.0%
$19.00
+196.9%
+28.3%$276.80M$7.03M-1.7496News Coverage
Gap Up
DNTH
Dianthus Therapeutics
2.5476 of 5 stars
$34.52
+0.3%
$60.88
+76.3%
+19.8%$1.11B$6.24M-10.6380
UPB
Upstream Bio
1.8454 of 5 stars
$20.15
+2.7%
$53.33
+164.7%
-11.6%$1.11B$2.37M0.0038
AMPH
Amphastar Pharmaceuticals
4.6851 of 5 stars
$23.53
+0.1%
$31.60
+34.3%
-51.3%$1.09B$731.97M8.822,028News Coverage
Analyst Forecast
LENZ
LENZ Therapeutics
2.4432 of 5 stars
$37.76
-2.2%
$52.80
+39.8%
+32.5%$1.08BN/A-19.95110Analyst Forecast
PRAX
Praxis Precision Medicines
2.4209 of 5 stars
$50.99
-2.6%
$85.56
+67.8%
+155.3%$1.08B$8.55M-4.16110Trending News
Analyst Forecast
Analyst Revision
SPRY
ARS Pharmaceuticals
3.1455 of 5 stars
$10.83
-0.9%
$33.80
+212.1%
-42.1%$1.07B$89.15M-22.1690
RLAY
Relay Therapeutics
2.0239 of 5 stars
$6.12
-2.3%
$16.50
+169.4%
-2.7%$1.05B$10.01M-3.13330
SEPN
Septerna
1.7184 of 5 stars
$23.43
-2.7%
$26.75
+14.2%
N/A$1.04B$1.08M-2.31N/A
SANA
Sana Biotechnology
2.6654 of 5 stars
$4.27
-1.6%
$7.50
+75.7%
+41.0%$1.02BN/A-4.04380
COLL
Collegium Pharmaceutical
3.7385 of 5 stars
$31.85
-0.6%
$42.33
+32.9%
-1.3%$1.01B$631.45M30.82210News Coverage

Related Companies and Tools


This page (NASDAQ:KYTX) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners